Skip to main content

Biogen VUMERITY revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

VUMERITY revenue at Biogen came to $192.0M for the quarter to 30 Sep 2026, down 10.5% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$156.4MDec 2023$127.5MMar 2024$165.8MJun 2024$158.1MSep 2024$176.6MDec 2024$138.8MMar 2025$212.3MJun 2025$214.6MSep 2025$181.1MDec 2025$179.0MMar 2026$196.5MJun 2026$192.0MSep 2026
Biogen VUMERITY revenue, every reported period
Period endingVUMERITY revenueChange on a yearFiled
30 Sep 2026$192.0Mdown 10.5%28 Oct 2026
30 Jun 2026$196.5Mdown 7.4%29 Jul 2026
31 Mar 2026$179.0Mup 29.0%29 Apr 2026
31 Dec 2025$181.1Mup 2.5%6 Feb 2026
30 Sep 2025$214.6Mup 35.7%30 Oct 2025
30 Jun 2025$212.3Mup 28.0%31 Jul 2025
31 Mar 2025$138.8Mup 8.9%1 May 2025
31 Dec 2024$176.6Mup 12.9%12 Feb 2025
30 Sep 2024$158.1Mdown 4.5%30 Oct 2024
30 Jun 2024$165.8Mup 13.4%1 Aug 2024
31 Mar 2024$127.5Mup 17.8%24 Apr 2024
31 Dec 2023$156.4Mup 3.7%14 Feb 2024
30 Sep 2023$165.5Mup 20.1%8 Nov 2023
30 Jun 2023$146.2Mup 6.9%25 Jul 2023
31 Mar 2023$108.2Mdown 15.5%25 Apr 2023
31 Dec 2022$150.8M—15 Feb 2023
30 Sep 2022$137.8Mup 14.0%25 Oct 2022
30 Jun 2022$136.8Mup 50.5%20 Jul 2022
31 Mar 2022$128.0M—3 May 2022
30 Sep 2021$120.9M—20 Oct 2021
30 Jun 2021$90.9M—22 Jul 2021

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.